Articles tagged with Cancer Patients
Adjuvant treatments with radiotherapy, chemotherapy, and hormone treatment tamoxifen can prevent late recurrences in breast cancer patients. The new findings show a significant decrease in deaths from breast cancer in middle-aged women, with a 30% fall over the past decade in the UK.
A Phase I/II study found substantial and occasional complete regression of widespread tumors in patients with treatment-resistant metastatic renal cell carcinoma treated with blood stem cell transplants. Three patients achieved total regression, while seven showed partial regression of disease.
The 2nd European Breast Cancer Conference will bring together over 3000 healthcare professionals, scientists, and patient advocates to share new developments in breast cancer research, treatment, and care. Distinguished international speakers will address key issues about the future of breast cancer research, treatment, and care.
A study found that six months of care for patients in phase II clinical trials costs $57,542, similar to $63,721 for those receiving standard treatment. This research suggests insurers can improve healthcare without financial risk.
A new laser treatment being tested at Rush University Medical Center has shown promise in eliminating the need for surgery in women with small breast cancers. The procedure uses a laser delivered through a needle to destroy tumors detected by mammography, resulting in no complications and minimal pain.
Researchers found that patients with localized prostate cancer who received higher doses of radiation lived longer and had better local control of their cancer. The study, published in the Journal of Clinical Oncology, examined data from 1560 patients treated between 1975 and 1995.
Patients with dementia often receive inadequate medical care due to a lack of data on the safety and efficacy of treatments. Guidelines need to consider a patient's ability to comprehend, remember, and follow directions, as well as their caregiver's capacity to listen and act.
A Phase III study found that a combination of histamine dihydrochloride and lower doses of interleukin-2 improved overall survival, increased survival rates at 12, 18, and 24 months, and reduced time-to-disease-progression compared to IL-2 alone. The treatment was well-tolerated and had substantially less toxicity.
Dr. Yoav Horn founded the West Bank Cancer Program in 1978, helping to establish two oncology treatment centers and train Palestinian physicians. The program improved early cancer treatment and saved lives, according to data from a computerized registry of over 7,000 patient records.
The study confirms that M-Vax increases the survival rate of patients with advanced Stage III melanoma, even after disease recurrence. Patients who developed an immune response against their melanoma had a far better outcome, with a five-year survival rate of 65%.
A study found that 40% of cancer patients use unconventional medical therapies and do not report this information unless specifically asked by their physicians. These therapies, such as mega-doses of vitamins and herbal supplements, can potentially interfere with radiation treatment.
The data from an ongoing Phase 1/2 trial of O-Vax in patients with advanced ovarian cancer indicates that the vaccine induces a positive immunological response, as measured by a delayed type hypersensitivity test. Favorable clinical responses were also observed, including complete regression of tumors and normalization of CA-125 levels.
A new study shows Bexxar produced tumor shrinkage in 97% of patients with advanced-stage, low-grade non-Hodgkins lymphoma. Most patients achieved complete remission, with no sign of cancer, and molecular remissions lasting up to three years.
The company presented Phase II data of tgDCC-E1A, a lead cancer therapy, which showed a 45% objective response rate in patients with recurrent head and neck squamous cell carcinoma. Preclinical studies also demonstrated the ability of E1A to sensitize tumors to radiation and chemotherapy.
A Phase III trial shows long-term hormone suppression can control recurrence and improve survival in prostate cancer patients. The treatment significantly reduces disease-free survival, local progression, and freedom from distant metastasis.
A Phase II trial found a 40% response rate with low-dose anti-VEGF combination therapy, compared to 24% for high-dose and 17% for chemotherapy alone. Median survival increased by 2 months with the low-dose treatment.
A study published at ASCO suggests that treating cancer patients on clinical trials is not more expensive than standard treatment. The research found average charges of $57,542 for trial patients and $63,721 for control patients, highlighting the potential for increased access to high-quality care.
Researchers have reported promising results from a Phase I-II trial of an ovarian cancer vaccine made from patient's own cancer cells. Eight of 10 patients showed immunological response, with one experiencing complete tumor disappearance and CA125 levels normalization.
A custom-made vaccine created from a patient's own cancer tumor cells has proven effective in prolonging the survival of patients with malignant melanoma. The vaccine resulted in a 47% five-year survival rate among 214 patients with disease spread, outperforming standard treatment.
A study found that elderly COPD patients who use inhaled steroids can significantly reduce their rehospitalization and death risk. Additionally, postmenopausal women are more likely to develop sleep apnea and have a severe form of the condition. Meanwhile, researchers discovered age bias in lung cancer treatment, with older patients be...
A study of 31 prostate cancer patients found that quality of life returns to normal within a year following brachytherapy, with urinary symptoms disappearing. The treatment was compared to other options like removal of the prostate or standard radiation therapy, which carry higher risks of decreased sexual function and bowel problems.
A new software program developed by Emory researchers uses data from 840 previous patients to predict outcomes in new patients. The genetic adaptive model has an accuracy rate of 76 percent and can help determine a patient's chances of cancer recurrence after treatment, guiding doctors towards the best treatment option.
A new study by University of North Carolina at Chapel Hill researchers shows a simple breath test can distinguish between patients who metabolize chemotherapy drugs normally and those who require lower doses for safety. The technique, which measures exhaled carbon dioxide, has promising advantages in reducing toxicity in patients.
A study of 42 breast cancer patients found that those who chose experimental treatments had higher levels of psychological distress, despite similar physical abilities. Researchers suggest that these women may feel a greater need to feel in control and desperate for effective treatment options.
Researchers at the University of Pennsylvania Cancer Center have successfully conducted a Phase I clinical trial on combretastatin A4 phosphate, a vascular targeting agent. The study found that patients with solid tumors were able to safely tolerate the treatment and showed evidence of decreased blood flow to the tumor.
OHSU researchers successfully delivered chemotherapy across the blood-brain barrier for patients with primary central nervous system lymphomas. The study showed that 93% of treated patients achieved a complete response and participating centers outperformed OHSU in blood-brain barrier disruptions.
A review paper by University of Pittsburgh researcher James J. Dignam suggests that physiological responses to treatments are not responsible for poorer outcomes among blacks. Black women with the same stage of breast cancer have more advanced disease conditions due to less access to or utilization of healthcare resources.
Researchers at the Mayo Clinic found that an experimental diode laser treatment controlled cancer growth in all but one patient with melanoma in the eye. No recurrences were noted in the remaining patients during follow-up periods.
A study published in Neurosurgery found that 42% of patients survived five years or more after receiving enhanced chemotherapy through blood-brain barrier disruption. The treatment also showed no cognitive loss or impairment in 36 patients, contrary to previous studies.
A new treatment approach combining traditional chemotherapy with medication delivered through an implanted pump has been found to significantly increase two-year survival rates and decrease tumor recurrence in patients with advanced colorectal cancer that has spread to the liver. The study, published in the New England Journal of Medic...
A study of over 6,000 patients found that one in every 100 people misdiagnosed due to a single pathologist's report. This can lead to incorrect treatment, surgery, or chemotherapy, causing psychological trauma and financial burden.
Researchers are examining whether high doses of vitamin D can stop the progression or destroy prostate cancer. If successful, patients may be able to delay aggressive treatment and stay on the treatment indefinitely.
Lung cancer treatment disparities between blacks and whites are attributed to racial attitudes and biases, affecting surgical resection rates and survival outcomes. UCSF specialists emphasize the importance of addressing these inequities through improved communication, screening tests, and clinical trials.
Researchers found that patients who previously received hormone therapy with tamoxifen, had no prior chemotherapy, and had limited metastases were more likely to live longer after high-dose chemotherapy with transplant. This study suggests that closely monitoring high-risk patients can improve treatment outcomes.
A nursing intervention program involving weekly telephone calls with nurses improves cancer patients' ability to manage symptoms, communicate concerns, and advocate for their own care. The program also benefits family caregivers, reducing time spent on managing side effects and improving quality of life.
Cancer patients who participate in regular physical exercise programs show significant improvements in physical and mental health, including enhanced stamina, muscle strength, and pain management. The studies found that exercise has a positive effect on quality of life, including functional, psychological, and emotional well-being.
A Mayo Clinic study reveals that many heart patients continue to take chest pain medications after undergoing angioplasty, suggesting a need for alternative treatment options. The gamma knife procedure is shown to be effective in treating various brain disorders, offering an alternative to surgery.
A study by the University of Pittsburgh Cancer Institute found that interferon alfa 2b significantly depresses the activity of internal enzymes breaking down narcotics and antidepressants. This may lead to overdose in cancer patients receiving these medications with IFNa2b.
Researchers have identified specific immune responses in patients treated with high doses of interferon alfa 2b to prevent melanoma recurrence. High-dose IFNa2b modulated the expression of MHC Class II antigens and increased natural killer cell activity, which may lead to better patient selection and therapy options.
Researchers have demonstrated a faster and safer approach to cancer vaccine therapy, producing encouraging results in melanoma patients. The new method involves using circulating white blood cells and moderate doses of IL-12, showing promise for treating advanced melanoma.
Researchers found that a small peptide, IM862, showed significant anti-angiogenesis activity in a human clinical trial, resulting in major responses in 37% of patients. The peptide inhibits blood vessel formation and modulates the immune system, offering a potential treatment for Kaposi's Sarcoma with improved safety profiles.
A retrospective statistical analysis of patients with advanced breast cancer found no survival benefit from high dose chemotherapy and bone marrow transplant. The study analyzed data from over 1,300 patients treated in the 1980s and early 1990s.
Researchers at Thomas Jefferson University have found that radiation therapy helps patients with localized prostate cancer live longer. After examining the results of 1560 patients who received radiation therapy alone for prostate cancer, they discovered that those with high-risk disease benefited the most from higher doses of radiation.
A USC study suggests that radiation therapy is not necessary for DCIS patients with margin widths of 10mm or more, and may even be counterproductive due to side effects and costs. Patients with narrower margins may benefit from postoperative radiation therapy.
The 'Demystifying Cancer' program brings together medical professionals, researchers, and experts to provide accurate information about cancer. Participants will learn about current therapies, clinical trials, and how to navigate the Internet for reliable information.
The Ablatherm device has shown local disease control in approximately 80% of cases, with a complete response in 56% and partial response in 24%. The treatment is minimally invasive and can be repeated if necessary, but may have some adverse effects.
The US Department of Energy's Brookhaven National Laboratory is offering a new clinical trial for brain tumor patients, including those whose cancer is inoperable or has regrown. The trial aims to increase the radiation dose and expand eligibility requirements for glioblastoma multiforme patients.
Researchers at Memorial Sloan-Kettering Cancer Center have shown that arsenic effectively induces remission in patients with acute promyelocytic leukemia (APL), a potentially fatal type of cancer. Eleven out of 12 patients achieved remission after treatment with low doses of arsenic trioxide, experiencing mild side effects.
Researchers are developing a new alternative treatment for cancer using radio-frequency ablation, which heats diseased cells with a fine electrode. The technique has shown promising results in treating liver cancers, with nine out of twelve patients remaining cancer-free for more than a year.
A study found that high-risk prostate cancer patients treated with seed implant therapy had poorer outcomes compared to radical prostectomy and external beam radiation. The researchers suggest that high-risk patients should discuss alternative treatment options with their physicians.
Researchers aim to prevent leukemia relapse by educating the immune system using immunotherapy and genetically modified cells. The new technology could eliminate second rounds of chemotherapy, reducing toxicity and hospital stays.
A new study found that patients with tumors expressing low levels of the tumor suppressor protein p21 are more likely to recur and die from bladder cancer than those with elevated p21 levels. The study suggests that knowing both p53 and p21 status is a more powerful indicator of risk, allowing for clearer treatment decisions.
A rare medical archive enabled researchers to determine that patients with high nm23 levels and low density of newly formed blood vessels were more likely to survive 14 years after treatment. Low micro-vessel count was also a predictor, with 92% of patients surviving at least 14 years.
A new study by Duke University Medical Center found that a combination of intensive, twice-daily radiation therapy and simultaneous chemotherapy can control cancer more frequently. The treatment resulted in a significant improvement in disease control and patient survival rates.
A new study found that daily pain among elderly nursing home residents with cancer is widespread and often untreated, especially among older and minority patients. The study highlights inadequate medical treatment and a need for improving pain management in these individuals.
In a Phase II study combining ONYX-015 with standard chemotherapy, nine out of ten patients experienced tumor regressions greater than 50 percent, including two complete responses. Thirty percent of patients treated with ONYX-015 alone showed significant tumor regression.
A phase III clinical trial suggests that suramin offers substantial pain reduction and moderate delay in disease progression for patients with advanced prostate cancer. The study involved 458 patients, who experienced significant pain reduction and a longer period of time compared to those receiving only hydrocortisone and a placebo.
Researchers at Thomas Jefferson University have created an autologous ovarian cancer vaccine that stimulates an immune response in patients, showing promise for treatment. The vaccine is custom-made for each patient and has been safe with no significant side effects, paving the way for further clinical trials.
A study by Memorial Sloan-Kettering Cancer Center found that 77% of adult AML patients who received a T-cell depleted bone marrow transplant were cancer-free after 6 years. The treatment limits graft-versus-host disease risk and leukemic recurrence.
Researchers at Thomas Jefferson University are conducting a gene therapy trial for glioblastoma, a form of brain cancer. The trial aims to delay disease progression and improve quality of life for patients, offering a potential cure for the deadliest type of brain tumor.